Skip to main content
PMC home page
Gut logoLink to Gut
. 2001 May;48(5):707–713. doi: 10.1136/gut.48.5.707

The epidemiology of hepatitis C in a UK health regional population of 5.12 million

A Mohsen 1, T H Group 1
PMCID: PMC1728264  PMID: 11302973

Abstract

BACKGROUND—The epidemiology and natural history of hepatitis C virus (HCV) infection in the UK are uncertain. Previous reports are from small or selected populations such as blood donors or tertiary referral centres.
AIMS—To study the epidemiology and natural history of HCV infection.
METHODS—Prospective study incorporating five centres within the Trent region. Patients were managed and followed up according to a commonly agreed protocol.
SUBJECTS—A total of 1128 HCV positive patients. Patients with haemophilia, human immunodeficiency virus, and chronic renal failure were excluded.
RESULTS—Between September 1991 and December 1998, 2546 anti-HCV positive patients were identified of whom 1128 (44%) were enrolled in the cohort. A risk factor(s) for infection was identified in 93.4% of patients who completed the questionnaire; 81% of patients were HCV RNA positive. A total of 397 initial liver biopsies were scored by a single pathologist. These showed a correlation between high alcohol intake and fibrosis score. Multivariate analysis showed fibrosis to be associated with age over 40, past evidence of hepatitis B virus infection, and higher necroinflammatory grade but not with sex, viral genotype, maximum known alcohol intake, estimated duration of infection, or mode of transmission. Twelve (7.8%) of 153 patients who received interferon therapy had sustained serum virus clearance. Sixty six patients have died during the follow up period, 31 with a liver related cause of death. This represents a considerable excess over the expected death rate for a cohort of this age and sex distribution.
CONCLUSIONS—HCV infection is an emerging health problem in the Trent region. Identifying risk factors for infection and disease severity will enhance understanding and facilitate improved intervention. An excess mortality in infected individuals is already evident in this unselected cohort.


Keywords: hepatitis C; epidemiology

Full Text

The Full Text of this article is available as a PDF (157.0 KB).

Figure 1  .

Figure 1  

Open in a new tab

Trent Hepatitis C Study Group assessment and management protocol (up to 1998). HCV, hepatitis C virus; LFTs, liver function tests; PCR, polymerase chain reaction.

Figure 2  .

Figure 2  

Open in a new tab

Percentage of new referrals on a yearly basis during the study period, 1991-1998.

Figure 3  .

Figure 3  

Open in a new tab

Highest known alcohol consumption in relation to hepatic fibrosis grades 3 and 4 in 331 patients with hepatitis C (numbers in boxes represent number of patients).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alter M. J. Epidemiology of hepatitis C in the West. Semin Liver Dis. 1995 Feb;15(1):5–14. doi: 10.1055/s-2007-1007259. [DOI] [PubMed] [Google Scholar]
  2. Alter M. J., Margolis H. S., Krawczynski K., Judson F. N., Mares A., Alexander W. J., Hu P. Y., Miller J. K., Gerber M. A., Sampliner R. E. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med. 1992 Dec 31;327(27):1899–1905. doi: 10.1056/NEJM199212313272702. [DOI] [PubMed] [Google Scholar]
  3. Bloom D. E. Technology, experimentation, and the quality of survey data. Science. 1998 May 8;280(5365):847–848. doi: 10.1126/science.280.5365.847. [DOI] [PubMed] [Google Scholar]
  4. Boxall E., Skidmore S., Evans C., Nightingale S. The prevalence of hepatitis B and C in an antenatal population of various ethnic origins. Epidemiol Infect. 1994 Dec;113(3):523–528. doi: 10.1017/s0950268800068539. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bukh J., Miller R. H., Purcell R. H. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis. 1995 Feb;15(1):41–63. doi: 10.1055/s-2007-1007262. [DOI] [PubMed] [Google Scholar]
  6. Cacciola I., Pollicino T., Squadrito G., Cerenzia G., Orlando M. E., Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med. 1999 Jul 1;341(1):22–26. doi: 10.1056/NEJM199907013410104. [DOI] [PubMed] [Google Scholar]
  7. Choo Q. L., Kuo G., Weiner A. J., Overby L. R., Bradley D. W., Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989 Apr 21;244(4902):359–362. doi: 10.1126/science.2523562. [DOI] [PubMed] [Google Scholar]
  8. Conry-Cantilena C., VanRaden M., Gibble J., Melpolder J., Shakil A. O., Viladomiu L., Cheung L., DiBisceglie A., Hoofnagle J., Shih J. W. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med. 1996 Jun 27;334(26):1691–1696. doi: 10.1056/NEJM199606273342602. [DOI] [PubMed] [Google Scholar]
  9. Darwish M. A., Faris R., Clemens J. D., Rao M. R., Edelman R. High seroprevalence of hepatitis A, B, C, and E viruses in residents in an Egyptian village in The Nile Delta: a pilot study. Am J Trop Med Hyg. 1996 Jun;54(6):554–558. doi: 10.4269/ajtmh.1996.54.554. [DOI] [PubMed] [Google Scholar]
  10. El-Serag H. B., Mason A. C. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999 Mar 11;340(10):745–750. doi: 10.1056/NEJM199903113401001. [DOI] [PubMed] [Google Scholar]
  11. Feinman S. V., Berris B., Bojarski S. Posttransfusion hepatitis in Toronto, Canada. Gastroenterology. 1988 Aug;95(2):464–469. doi: 10.1016/0016-5085(88)90505-7. [DOI] [PubMed] [Google Scholar]
  12. Flamm S. L., Parker R. A., Chopra S. Risk factors associated with chronic hepatitis C virus infection: limited frequency of an unidentified source of transmission. Am J Gastroenterol. 1998 Apr;93(4):597–600. doi: 10.1111/j.1572-0241.1998.171_b.x. [DOI] [PubMed] [Google Scholar]
  13. Foster G. R., Goldin R. D., Main J., Murray-Lyon I., Hargreaves S., Thomas H. C. Management of chronic hepatitis C: clinical audit of biopsy based management algorithm. BMJ. 1997 Aug 23;315(7106):453–458. doi: 10.1136/bmj.315.7106.453. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Frischer M., Goldberg D., Rahman M., Berney L. Mortality and survival among a cohort of drug injectors in Glasgow, 1982-1994. Addiction. 1997 Apr;92(4):419–427. [PubMed] [Google Scholar]
  15. Goldberg D., Cameron S., McMenamin J. Hepatitis C virus antibody prevalence among injecting drug users in Glasgow has fallen but remains high. Commun Dis Public Health. 1998 Jun;1(2):95–97. [PubMed] [Google Scholar]
  16. Harris K. A., Gilham C., Mortimer P. P., Teo C. G. The most prevalent hepatitis C virus genotypes in England and Wales are 3a and 1a. J Med Virol. 1999 Jun;58(2):127–131. doi: 10.1002/(sici)1096-9071(199906)58:2<127::aid-jmv5>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  17. Irving W. L., Neal K. R., Underwood J. C., Simmonds P. N., James V. Chronic hepatitis in United Kingdom blood donors infected with hepatitis C virus. Trent Regional Hepatitis C Virus Study Group. BMJ. 1994 Mar 12;308(6930):695–696. doi: 10.1136/bmj.308.6930.695. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Knodell R. G., Ishak K. G., Black W. C., Chen T. S., Craig R., Kaplowitz N., Kiernan T. W., Wollman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981 Sep-Oct;1(5):431–435. doi: 10.1002/hep.1840010511. [DOI] [PubMed] [Google Scholar]
  19. McHutchison J. G., Gordon S. C., Schiff E. R., Shiffman M. L., Lee W. M., Rustgi V. K., Goodman Z. D., Ling M. H., Cort S., Albrecht J. K. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998 Nov 19;339(21):1485–1492. doi: 10.1056/NEJM199811193392101. [DOI] [PubMed] [Google Scholar]
  20. Neal K. R., Jones D. A., Killey D., James V. Risk factors for hepatitis C virus infection. A case-control study of blood donors in the Trent Region (UK). Epidemiol Infect. 1994 Jun;112(3):595–601. doi: 10.1017/s0950268800051293. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Poynard T., Bedossa P., Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997 Mar 22;349(9055):825–832. doi: 10.1016/s0140-6736(96)07642-8. [DOI] [PubMed] [Google Scholar]
  22. Poynard T., Leroy V., Cohard M., Thevenot T., Mathurin P., Opolon P., Zarski J. P. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology. 1996 Oct;24(4):778–789. doi: 10.1002/hep.510240405. [DOI] [PubMed] [Google Scholar]
  23. Poynard T., Marcellin P., Lee S. S., Niederau C., Minuk G. S., Ideo G., Bain V., Heathcote J., Zeuzem S., Trepo C. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) Lancet. 1998 Oct 31;352(9138):1426–1432. doi: 10.1016/s0140-6736(98)07124-4. [DOI] [PubMed] [Google Scholar]
  24. Roudot-Thoraval F., Bastie A., Pawlotsky J. M., Dhumeaux D. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus. Hepatology. 1997 Aug;26(2):485–490. doi: 10.1002/hep.510260233. [DOI] [PubMed] [Google Scholar]
  25. Schreiber G. B., Busch M. P., Kleinman S. H., Korelitz J. J. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med. 1996 Jun 27;334(26):1685–1690. doi: 10.1056/NEJM199606273342601. [DOI] [PubMed] [Google Scholar]
  26. Seeff L. B., Buskell-Bales Z., Wright E. C., Durako S. J., Alter H. J., Iber F. L., Hollinger F. B., Gitnick G., Knodell R. G., Perrillo R. P. Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group. N Engl J Med. 1992 Dec 31;327(27):1906–1911. doi: 10.1056/NEJM199212313272703. [DOI] [PubMed] [Google Scholar]
  27. Serfaty L., Chazouillères O., Poujol-Robert A., Morand-Joubert L., Dubois C., Chrétien Y., Poupon R. E., Petit J. C., Poupon R. Risk factors for cirrhosis in patients with chronic hepatitis C virus infection: results of a case-control study. Hepatology. 1997 Sep;26(3):776–779. doi: 10.1002/hep.510260334. [DOI] [PubMed] [Google Scholar]
  28. Tong M. J., el-Farra N. S., Reikes A. R., Co R. L. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med. 1995 Jun 1;332(22):1463–1466. doi: 10.1056/NEJM199506013322202. [DOI] [PubMed] [Google Scholar]
  29. Wiley T. E., McCarthy M., Breidi L., McCarthy M., Layden T. J. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology. 1998 Sep;28(3):805–809. doi: 10.1002/hep.510280330. [DOI] [PubMed] [Google Scholar]
  30. Wreghitt T. G., Gray J. J., Allain J. P., Poulain J., Garson J. A., Deaville R., Maple C., Parameshwar J., Calne R. Y., Wallwork J. Transmission of hepatitis C virus by organ transplantation in the United Kingdom. J Hepatol. 1994 Jun;20(6):768–772. doi: 10.1016/s0168-8278(05)80148-5. [DOI] [PubMed] [Google Scholar]
  31. Zein N. N., Rakela J., Krawitt E. L., Reddy K. R., Tominaga T., Persing D. H. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Ann Intern Med. 1996 Oct 15;125(8):634–639. doi: 10.7326/0003-4819-125-8-199610150-00002. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES